Abivax SA ADR (ABVX)
Abivax's inflammatory bowel drug meets main goal of late stage trial
Abivax said on Monday its experimental drug for patients with ulcerative colitis, a type of chronic inflammatory disease, met the main goal of a closely watched late-stage trial.
What Makes Abivax SA Sponsored ADR (ABVX) a Strong Momentum Stock: Buy Now?
Does Abivax SA Sponsored ADR (ABVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Abivax: Obefazimod's Strategic Scarcity Drives Optionality (Maintaining Buy)
Abivax remains a buy, with Obefezimod showing best-in-class efficacy and safety in ulcerative colitis and potential in Crohn's disease. Updated phase 3 and UEG safety data further de-risk ABVX, supporting earlier line use and expanding market potential beyond refractory patients. I raise my probability of success to 95%, increasing the 12-month target price to $140 per share, reflecting ~25% upside.
Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC
Abivax CEO Marc de Garidel told CNBC that the terms of any future deal will be better after it releases data on a key trial in the second quarter. Intense takeover rumors have surrounded the French biotech company for months, with analysts seeing it as a prime takeover target.
Abivax spokesperson denies takeover rumors reported by French media
Biotechnology company Abivax dismissed information published by French media publication "La Lettre" saying it had granted AstraZeneca exclusive access to confidential information until March 23 to allow the British pharmaceutical giant to formalise a takeover offer.
Alger Mid Cap Growth Fund Q4 2025 Portfolio Update
Class A shares of the Alger Mid Cap Growth Fund outperformed the Russell Midcap Growth Index during the fourth quarter of 2025. Cidara Therapeutics, Inc., Natera, Inc., and Abivax were among the top contributors to performance. Roblox Corp. Class A, e.l.f. Beauty, Inc., and Nebius Group were among the top detractors from performance.
Abivax CEO dismisses 'noise' around rumored Eli Lilly bid
Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly may take over his company, and said market speculation about an ongoing review by French authorities was inconsistent with how French foreign-investment oversight works.
Abivax: Don't Just Buy The Rumor, Buy The Fundamentals
Abivax (ABVX) remains a Buy, driven by obefazimod's strong UC data and significant multi-billion dollar market potential. ABVX is a credible M&A target, with Eli Lilly and other pharma giants rumored as potential acquirers, but fundamentals—not acquisition hopes—should drive investment decisions. Key 2026 catalysts include Phase 3 UC maintenance topline data, potential NDA/MAA filings, and Phase 2B Crohn's disease results.
France has had no request for investment approval in biotech Abivax - official
France's finance ministry has received no request seeking investment approval in Abivax and has had no contact with Eli Lilly , a ministry official said on Monday, following media reports that the U.S. pharma giant was still interested in buying the French biotech firm.
Abivax Surges on Report Ely Lily is Preparing $17.5 Billion Bid
Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.
Abivax shares soar 23% as media report reignites M&A chatter
Shares in Abivax soared 23%, exceeding 121 euros, on Monday after a media report said U.S. pharma giant Eli Lilly was still interested in buying the French biotech company.
Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
Abivax surged 1,470% YTD, driven by Obefazimod's clinical progress and takeover speculation, but I rate it Hold due to valuation risk. Obefazimod, a first-in-class oral therapy for ulcerative colitis, met key Phase 3 endpoints, with pivotal maintenance data expected mid-2026. ABVX boasts €589.7 million in cash, supporting operations through Q4 2027, despite high R&D-driven losses and a €15.3 million monthly cash burn.
